The Evolving Role of Cytokine-Based Therapy in Patients With Melanoma Progression and/or Drug Resistance

In this commentary, an expert explains how high-dose IL-2 continues to have a role in the management of resistant or progressive melanoma and discusses evolving ways to incorporate IL-2 therapy into melanoma care.

Elizabeth Buchbinder, MD Released: February 15, 2021

This downloadable slideset from an ondemand webcast provides an overview of the current treatment landscape in advanced melanoma including evidence on targeted therapy, immunotherapy, and combinations.

Ahmad Tarhini, MD, PhD Released: April 2, 2021

This downloadable slideset from an ondemand webcast offers insight into best practices for the management of adverse events associated with different classes of agents used for advanced melanoma including targeted therapy, immunotherapy, and high-dose IL2 therapy.

George Ebanks, RN, BSN, OCN Jennifer Swank, PharmD, BCOP Released: April 2, 2021

This downloadable slideset from an ondemand webcast explores the role of cytokine therapy and emerging strategies in the management of resistant or progressive melanoma. 

Ahmad Tarhini, MD, PhD Released: April 2, 2021

Download this summary slideset with a brief review the current treatment landscape in advanced melanoma and the role of cytokine-based therapy in progressive or resistant melanoma.

George Ebanks, RN, BSN, OCN Jennifer Swank, PharmD, BCOP Ahmad Tarhini, MD, PhD Released: April 2, 2021

Learn how experts leverage cytokine therapy for optimal treatment of patients with advanced melanoma in this on-demand webcast capturing a live CCO webinar.

Ahmad Tarhini, MD, PhD
Program Director George Ebanks, RN, BSN, OCN Jennifer Swank, PharmD, BCOP Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: April 8, 2021 Expired: No longer available for credit

The Current Treatment Landscape in Advanced Melanoma (12 mins)

BRAF/MEK Inhibitors and High-Dose IL-2 in Melanoma: Adverse Event Management (30 mins)

Emerging Strategies for Resistant or Progressive Disease (12 mins)